476 related articles for article (PubMed ID: 9174360)
1. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.
Stoll VS; Simpson SJ; Krauth-Siegel RL; Walsh CT; Pai EF
Biochemistry; 1997 May; 36(21):6437-47. PubMed ID: 9174360
[TBL] [Abstract][Full Text] [Related]
2. The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state.
Lantwin CB; Schlichting I; Kabsch W; Pai EF; Krauth-Siegel RL
Proteins; 1994 Feb; 18(2):161-73. PubMed ID: 8159665
[TBL] [Abstract][Full Text] [Related]
3. Redox enzyme engineering: conversion of human glutathione reductase into a trypanothione reductase.
Bradley M; Bücheler US; Walsh CT
Biochemistry; 1991 Jun; 30(25):6124-7. PubMed ID: 2059620
[TBL] [Abstract][Full Text] [Related]
4. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies.
Gallwitz H; Bonse S; Martinez-Cruz A; Schlichting I; Schumacher K; Krauth-Siegel RL
J Med Chem; 1999 Feb; 42(3):364-72. PubMed ID: 9986706
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the Trypanosoma cruzi trypanothione reductase.mepacrine complex.
Jacoby EM; Schlichting I; Lantwin CB; Kabsch W; Krauth-Siegel RL
Proteins; 1996 Jan; 24(1):73-80. PubMed ID: 8628734
[TBL] [Abstract][Full Text] [Related]
6. The parasite-specific trypanothione metabolism of trypanosoma and leishmania.
Krauth-Siegel RL; Meiering SK; Schmidt H
Biol Chem; 2003 Apr; 384(4):539-49. PubMed ID: 12751784
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking of a series of peptidomimetics in the trypanothione binding site of T. cruzi trypanothione reductase.
da Rocha Pita SS; Cirino JJ; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
J Mol Graph Model; 2009 Nov; 28(4):330-5. PubMed ID: 19766515
[TBL] [Abstract][Full Text] [Related]
8. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
9. Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme.
Krauth-Siegel RL; Enders B; Henderson GB; Fairlamb AH; Schirmer RH
Eur J Biochem; 1987 Apr; 164(1):123-8. PubMed ID: 3549299
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and characterization of Leishmania donovani trypanothione reductase in Escherichia coli.
Mittal MK; Misra S; Owais M; Goyal N
Protein Expr Purif; 2005 Apr; 40(2):279-86. PubMed ID: 15766869
[TBL] [Abstract][Full Text] [Related]
11. Docking and molecular dynamics studies at trypanothione reductase and glutathione reductase active sites.
Iribarne F; Paulino M; Aguilera S; Murphy M; Tapia O
J Mol Model; 2002 May; 8(5):173-83. PubMed ID: 12111385
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors.
Bond CS; Zhang Y; Berriman M; Cunningham ML; Fairlamb AH; Hunter WN
Structure; 1999 Jan; 7(1):81-9. PubMed ID: 10368274
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of substrate analogue inhibitors of trypanothione reductase.
Duyzend MH; Clark CT; Simmons SL; Johnson WB; Larson AM; Leconte AM; Wills AW; Ginder-Vogel M; Wilhelm AK; Czechowicz JA; Alberg DG
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):784-94. PubMed ID: 22085139
[TBL] [Abstract][Full Text] [Related]
14. Engineering the substrate specificity of glutathione reductase toward that of trypanothione reduction.
Henderson GB; Murgolo NJ; Kuriyan J; Osapay K; Kominos D; Berry A; Scrutton NS; Hinchliffe NW; Perham RN; Cerami A
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8769-73. PubMed ID: 1924337
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of the human thioltransferase (glutaredoxin) C7S, C25S, C78S, C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity.
Yang Y; Jao Sc; Nanduri S; Starke DW; Mieyal JJ; Qin J
Biochemistry; 1998 Dec; 37(49):17145-56. PubMed ID: 9860827
[TBL] [Abstract][Full Text] [Related]
16. Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds.
Jockers-Scherübl MC; Schirmer RH; Krauth-Siegel RL
Eur J Biochem; 1989 Mar; 180(2):267-72. PubMed ID: 2647489
[TBL] [Abstract][Full Text] [Related]
17. Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution.
Bailey S; Fairlamb AH; Hunter WN
Acta Crystallogr D Biol Crystallogr; 1994 Mar; 50(Pt 2):139-54. PubMed ID: 15299452
[TBL] [Abstract][Full Text] [Related]
18. Trypanothione biosynthesis in Leishmania major.
Oza SL; Shaw MP; Wyllie S; Fairlamb AH
Mol Biochem Parasitol; 2005 Jan; 139(1):107-16. PubMed ID: 15610825
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of parasite trypanothione reductase: acquisition of glutathione reductase activity in a triple mutant.
Sullivan FX; Sobolov SB; Bradley M; Walsh CT
Biochemistry; 1991 Mar; 30(11):2761-7. PubMed ID: 2007114
[TBL] [Abstract][Full Text] [Related]
20. New enzymes for old: redesigning the coenzyme and substrate specificities of glutathione reductase.
Perham RN; Scrutton NS; Berry A
Bioessays; 1991 Oct; 13(10):515-25. PubMed ID: 1755827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
